Integrating chemoradiation and molecularly targeted therapy

This publication has 109 references indexed in Scilit:

• Exploiting CTLA-4, PD-1 and PD-L1 to reactivate the host immune response against cancer
  British Journal of Cancer, 2013
• Immunologic Correlates of the Abscopal Effect in a Patient with Melanoma
  New England Journal of Medicine, 2012
• Addition of bevacizumab to standard chemoradiation for locoregionally advanced nasopharyngeal carcinoma (RTOG 0615): a phase 2 multi-institutional trial
  The Lancet Oncology, 2012
• Wee1 controls genomic stability during replication by regulating the Mus81-Eme1 endonuclease
  Journal of Cell Biology, 2011
• Targeting Nonhomologous End-Joining Through Epidermal Growth Factor Receptor Inhibition: Rationale and Strategies for Radiosensitization
  Seminars in Radiation Oncology, 2010
• Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
  New England Journal of Medicine, 2010
• PARP inhibition: PARP1 and beyond
  Nature Reviews Cancer, 2010
• Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): An update on 93 randomised trials and 17,346 patients
  Radiotherapy and Oncology, 2009
• Inhibition of Phosphatidylinositol-3-OH Kinase/Akt Signaling Impairs DNA Repair in Glioblastoma Cells following Ionizing Radiation
  Journal of Biological Chemistry, 2007
• Radiotherapy plus Concomitant and Adjuvant Temozolomide for Glioblastoma
  New England Journal of Medicine, 2005